Form 4: Phio Pharma Director Receives 14,700 Restricted Stock Units

Phio Pharmaceuticals Corp. Director Jonathan E. Freeman was granted 14,700 restricted stock units, vesting in one year, increasing his beneficial ownership to 16,055 shares.

Summary

• Jonathan E. Freeman, a Director of Phio Pharmaceuticals Corp. (PHIO), acquired 14,700 shares of common stock.
• These shares represent restricted stock units (RSUs) granted on September 11, 2025.
• The RSUs will vest on the first annual anniversary of the grant date.
• Following this transaction, Freeman's total beneficial ownership in Phio Pharmaceuticals Corp. is 16,055 shares, which includes other unvested restricted stock units.
• The reported share count has been adjusted for prior reverse stock splits.
• A Power of Attorney was filed, appointing Lisa C. Carson and Irina Abbas as attorneys-in-fact for Freeman's SEC filings.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is generally a positive signal, indicating continued alignment of interests and retention, though it's not a direct cash investment.

Positives

• The grant of restricted stock units to a director aligns management's interests with long-term shareholder value.
• Increased beneficial ownership by a director can signal confidence in the company's future prospects.

Negatives

• The transaction price of $0 for the acquired shares indicates a grant rather than an open market purchase, which does not represent a direct cash investment by the director.

Future Outlook

The 14,700 restricted stock units granted to Director Jonathan E. Freeman are scheduled to vest on the first annual anniversary of the grant date, which is September 11, 2026.

Industry Context

The grant of restricted stock units is a common form of equity compensation for directors and executives across various industries, designed to align their interests with long-term shareholder value.

Related Party Transactions

• The grant of 14,700 restricted stock units to Director Jonathan E. Freeman constitutes a related party transaction, common for executive compensation.

Stakeholder Impact

• Shareholders: The grant of RSUs aligns the director's long-term interests with shareholder value, potentially encouraging decisions that benefit the stock price.

Next Steps

• The 14,700 restricted stock units are expected to vest on September 11, 2026.

Key Dates

Recommendation

The filing details a routine grant of restricted stock units to a director, which is a common form of equity compensation. While it aligns the director's interests with long-term shareholder value, it does not represent a direct cash investment or provide new material information to warrant a change in investment stance. Therefore, a 'hold' recommendation is appropriate based solely on this filing.

Keywords

Phio Pharmaceuticals, PHIO, Jonathan E. Freeman, Restricted Stock Units, RSU, Insider Trading, Form 4, Beneficial Ownership, Director Compensation, Equity Grant